Annual report pursuant to Section 13 and 15(d)

Intangible Assets and Impairment of Long-Lived Assets (Details) - Schedule of Goodwill Activity

v3.24.1
Intangible Assets and Impairment of Long-Lived Assets (Details) - Schedule of Goodwill Activity - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
CBR Pharma Goodwill [Member]    
Schedule of Goodwill Activity [Line Items]    
Balance at beginning $ 23,749,631
Balance at ending  
Currency translation   (3,440,608)
Impairment of goodwill   (20,309,023)
180 LP Goodwill [Member]    
Schedule of Goodwill Activity [Line Items]    
Balance at beginning 13,238,255
Balance at ending  
Currency translation  
Impairment of goodwill   (13,328,255)
Consolidated Goodwill [Member]    
Schedule of Goodwill Activity [Line Items]    
Balance at beginning 36,987,886
Balance at ending  
Currency translation   (3,440,608)
Impairment of goodwill   (33,547,278)
CBR Pharma IP R&D Assets [Member]    
Schedule of Goodwill Activity [Line Items]    
Balance at beginning 1,632,780
Balance at ending
Currency translation   (170,696)
Impairment of IP R&D assets (1,462,084)
180 LP IP R&D Assets [Member]    
Schedule of Goodwill Activity [Line Items]    
Balance at beginning 9,063,000 10,943,000
Balance at ending 9,063,000
Currency translation  
Impairment of IP R&D assets (9,063,000) (1,880,000)
Consolidated IP R&D Assets [Member]    
Schedule of Goodwill Activity [Line Items]    
Balance at beginning 9,063,000 12,575,780
Balance at ending 9,063,000
Currency translation   (170,696)
Impairment of IP R&D assets $ (9,063,000) $ (3,342,084)